
Company achieves breakthrough in transcriptomic drug discovery
QUANTRO Therapeutics has successfully completed its first 10-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple molecular targets. After establishing its technology for single- and dual-target screenings at a current capacity of approximately one million compounds per year, QUANTRO has… Read More










